U.S., Jan. 28 -- ClinicalTrials.gov registry received information related to the study (NCT07368985) titled 'Pembrolizumab and Lenvatinib in Patients With High Risk Locally Advanced Cervix Cancer' on Jan. 22.
Brief Summary: The goal of this clinical trial is to learn if the combination of Pembrolizumab and Lenvatinib works to treat locally advanced cervical cancer in adults that will undergo primary chemoradiation and brachytherapy. It will also learn about the safety of the combination of Pembrolizumab and Lenvatinib. The main questions it aims to answer are:
* Does the combination of Pembrolizumab and Lenvatinib improve progression free survival at two years after treatment?
* What side effects do participants have when taking the comb...